title: Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
abstract: There is no data on safety and efficacy of a second course of ibritumomab tiuxetan. In this work, data on patients with B-cell NHL who were treated with two courses of ibritumomab tiuxetan were analyzed. Eighteen such patients were analyzed (age: 58 years, 48 - 91), with a median of four prior regimens (1 - 7), stem cell transplantation (n = 5), and radiation therapy (n = 6). After the first course, G3/4 neutropenia and thrombocytopenia was 35% and 41%; overall response rate (ORR) was 89%; time between courses was 16.6 months (6.0 - 42.7). After the second course, the incidence of G3/4 neutropenia and thrombocytopenia was 28% and 44%; and ORR 77%. There were no infectious or bleeding complications, secondary myelodysplastic syndromes, or leukemias. Retreatment with the ibritumomab tiuxetan regimen was well tolerated, with a safety profile similar to that of the first course. To conclude, patients who benefited from the first course of ibritumomab tiuxetan can benefit from retreatment.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA.
authors.forename: Jatin
authors.initials: J
authors.lastname: Shah
authors.forename: Wenquan
authors.initials: W
authors.lastname: Wang
authors.forename: V Douglas
authors.initials: VD
authors.lastname: Harrough
authors.forename: Wayne
authors.initials: W
authors.lastname: Saville
authors.forename: Ruby
authors.initials: R
authors.lastname: Meredith
authors.forename: Sui
authors.initials: S
authors.lastname: Shen
authors.forename: John
authors.initials: J
authors.lastname: Mueh
authors.forename: John
authors.initials: J
authors.lastname: Lister
authors.forename: Sri
authors.initials: S
authors.lastname: Jasthy
authors.forename: Gregory
authors.initials: G
authors.lastname: Maggass
authors.forename: Charles
authors.initials: C
authors.lastname: McKay
authors.forename: Richard
authors.initials: R
authors.lastname: Krumdieck
authors.forename: Morgan
authors.initials: M
authors.lastname: Tharp
authors.forename: Christine
authors.initials: C
authors.lastname: Winter
authors.forename: Stephanie
authors.initials: S
authors.lastname: Gregory
authors.forename: William
authors.initials: W
authors.lastname: Buchholz
authors.forename: Sanjay
authors.initials: S
authors.lastname: Awasthi
authors.forename: Samuel
authors.initials: S
authors.lastname: Jacobs
authors.forename: Harold
authors.initials: H
authors.lastname: Chung
authors.forename: James
authors.initials: J
authors.lastname: Egner
authors.forename: Albert F
authors.initials: AF
authors.lastname: Lobuglio
authors.forename: Andres
authors.initials: A
authors.lastname: Forero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy; D012189:Retrospective Studies; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*